Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Etienne Brain

Showing results (91-100 of 139) with videos related to

Pageof 14
Sort By:
The Lancet. Oncology|May 17, 2011
TP53 status for prediction of sensitivity to taxane versus non-taxane neoadjuvant chemotherapy in breast cancer (EORTC 10994/BIG 1-00): a randomised phase 3 trialHervé Bonnefoi, Martine Piccart, Jan Bogaerts, et al.
Breast Cancer (Tokyo, Japan)|January 11, 2023
Clinical outcome of patients with isolated central nervous system progression on first-line pertuzumab and trastuzumab treatment for HER2-positive metastatic breast cancer in a real-life cohortLaetitia Collet, Lauriane Eberst, Gauthier Ludovic, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 9, 2016
Biomarker Associations with Efficacy of Abiraterone Acetate and Exemestane in Postmenopausal Patients with Estrogen Receptor-Positive Metastatic Breast CancerWeimin Li, Joyce O'Shaughnessy, Daniel Hayes, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 17, 2026
Transcriptomic insights into lobular breast cancer biology and patient outcomes: analysis of the MINDACT clinical trialChristine Desmedt, Ha-Linh Nguyen, François Richard, et al.
Frontiers in Medicine|January 31, 2022
ERANET JTC 2011: Submission and Activation of an International Academic Translational Project in Advanced Breast Cancer. Experience From the ET-FES StudyManuela Monti, Tom Degenhardt, Etienne Brain, et al.
JAMA Oncology|August 10, 2023
Pertuzumab Plus Trastuzumab With or Without Chemotherapy Followed by Emtansine in ERBB2-Positive Metastatic Breast Cancer: A Secondary Analysis of a Randomized Clinical TrialJens Huober, Patrik Weder, Karin Ribi, et al.
Pharmaceuticals (Basel, Switzerland)|November 26, 2020
VEGF-Related Germinal Polymorphisms May Identify a Subgroup of Breast Cancer Patients with Favorable Outcome under Bevacizumab-Based Therapy-A Message from COMET, a French Unicancer Multicentric StudyJocelyn Gal, Gérard Milano, Patrick Brest, et al.
Therapeutic Advances in Medical Oncology|January 25, 2021
Management and outcome of male metastatic breast cancer in the national multicenter observational research program Epidemiological Strategy and Medical Economics (ESME)Junien Sirieix, Julien Fraisse, Simone Mathoulin-Pelissier, et al.
European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology|December 30, 2023
Impact of guideline adherence and expert center referral on the early management and outcomes of uterine sarcoma patients: A retrospective analysis from the French NETSARC networkClarisse Richaud, Floriane Jochum, Gabrielle Journo, et al.
Breast (Edinburgh, Scotland)|May 20, 2026
Characteristics and outcomes of patients with HER2-negative metastatic breast cancers with low expression of estrogen and progesterone receptors in the multicenter ESME cohortMarie Alexandre, Eva Teruel, Florence Dalenc, et al.
Pageof 14

Showing results (91-100 of 139) with videos related to

Sort By:
Pageof 14
The Lancet. Oncology|May 17, 2011
TP53 status for prediction of sensitivity to taxane versus non-taxane neoadjuvant chemotherapy in breast cancer (EORTC 10994/BIG 1-00): a randomised phase 3 trialHervé Bonnefoi, Martine Piccart, Jan Bogaerts, et al.
Breast Cancer (Tokyo, Japan)|January 11, 2023
Clinical outcome of patients with isolated central nervous system progression on first-line pertuzumab and trastuzumab treatment for HER2-positive metastatic breast cancer in a real-life cohortLaetitia Collet, Lauriane Eberst, Gauthier Ludovic, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 9, 2016
Biomarker Associations with Efficacy of Abiraterone Acetate and Exemestane in Postmenopausal Patients with Estrogen Receptor-Positive Metastatic Breast CancerWeimin Li, Joyce O'Shaughnessy, Daniel Hayes, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 17, 2026
Transcriptomic insights into lobular breast cancer biology and patient outcomes: analysis of the MINDACT clinical trialChristine Desmedt, Ha-Linh Nguyen, François Richard, et al.
Frontiers in Medicine|January 31, 2022
ERANET JTC 2011: Submission and Activation of an International Academic Translational Project in Advanced Breast Cancer. Experience From the ET-FES StudyManuela Monti, Tom Degenhardt, Etienne Brain, et al.
JAMA Oncology|August 10, 2023
Pertuzumab Plus Trastuzumab With or Without Chemotherapy Followed by Emtansine in ERBB2-Positive Metastatic Breast Cancer: A Secondary Analysis of a Randomized Clinical TrialJens Huober, Patrik Weder, Karin Ribi, et al.
Pharmaceuticals (Basel, Switzerland)|November 26, 2020
VEGF-Related Germinal Polymorphisms May Identify a Subgroup of Breast Cancer Patients with Favorable Outcome under Bevacizumab-Based Therapy-A Message from COMET, a French Unicancer Multicentric StudyJocelyn Gal, Gérard Milano, Patrick Brest, et al.
Therapeutic Advances in Medical Oncology|January 25, 2021
Management and outcome of male metastatic breast cancer in the national multicenter observational research program Epidemiological Strategy and Medical Economics (ESME)Junien Sirieix, Julien Fraisse, Simone Mathoulin-Pelissier, et al.
European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology|December 30, 2023
Impact of guideline adherence and expert center referral on the early management and outcomes of uterine sarcoma patients: A retrospective analysis from the French NETSARC networkClarisse Richaud, Floriane Jochum, Gabrielle Journo, et al.
Breast (Edinburgh, Scotland)|May 20, 2026
Characteristics and outcomes of patients with HER2-negative metastatic breast cancers with low expression of estrogen and progesterone receptors in the multicenter ESME cohortMarie Alexandre, Eva Teruel, Florence Dalenc, et al.
Pageof 14